MARON
AND MCKENNA et al., ACC/ESC Expert Consensus Document on Hypertrophic
Cardiomyopathy
JACC 2003; 42:
000-000
American
College of Cardiology/European Society of Cardiology Clinical
Expert Consensus Document on Hypertrophic Cardiomyopathy
A
Report of the American College of Cardiology Foundation Task
Force on Clinical Expert Consensus Documents and the European
Society of Cardiology Committee for Practice Guidelines
References
1.
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild
DE. Prevalence of hypertrophic cardiomyopathy in a general
population of young adults. Echocardiographic analysis of
4111 subjects in the CARDIA Study. Coronary Artery Risk Development
in (Young) Adults. Circulation 1995;92:785–9.
2.
Ferrans VJ, Morrow AG, Roberts WC. Myocardial ultrastructure
in idiopathic hypertrophic subaortic stenosis. A study of
operatively excised left ventricular outflow tract muscle
in 14 patients. Circulation 1972;45:769–92.
3.
Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis.
Clinical analysis of 126 patients with emphasis on the natural
history. Circulation 1968;37:759–88.
4.
Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle
cell disorganization in the ventricular septum of patients
with hypertrophic cardiomyopathy. Circulation 1979;59:689–706.
5.
Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–33.
6.
Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory
molecular diagnosis on contemporary diagnostic criteria for
genetically transmitted cardiovascular diseases: hypertrophic
cardiomyopathy, long-QT syndrome, and Marfan syndrome. [A
statement for healthcare professionals from the Councils on
Clinical Cardiology, Cardiovascular Disease in the Young,
and Basic Science, American Heart Association]. Circulation
1998;98:1460–71.
7.
Maron BJ. Hypertrophic cardiomyopathy: a systematic review.
JAMA 2002;287:1308–20.
8.
Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment
in hypertrophic subaortic stenosis. Techniques, and the results
of pre and postoperative assessments in 83 patients. Circulation
1975;52:88–102.
9.
Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis
of familial cardiomyopathies. Circulation 1995;91:532–40.
10.
Shah PM, Adelman AG, Wigle ED, et al. The natural (and unnatural)
history of hypertrophic obstructive cardiomyopathy. Circ Res
1974;35 Suppl II:179–95.
11.
Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management
of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775–85.
12.
Teare D. Asymmetrical hypertrophy of the heart in young adults.
Br Heart J 1958;20:1–18.
13.
Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy.
The importance of the site and the extent of hypertrophy.
A review. Prog Cardiovasc Dis 1985;28:1–83.
14.
Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic
cardiomyopathy. Clinical spectrum and treatment. Circulation
1995;
92:1680–92.
15.
Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J,
Trusler GA. Results of surgery for hypertrophic obstructive
cardiomyopathy. Circulation 1987;76:V104–8.
16.
Maron BJ, Carney KP, Lever HM, et al. Relationship of race
to sudden cardiac death in competitive athletes with hypertrophic
cardiomyopathy. J Am Coll Cardiol 2003;41:974–80.
17.
Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations
in the gene for cardiac myosin-binding protein C and late-onset
familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248–57.
18.
Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin
and cardiac troponin T mutations cause familial hypertrophic
cardiomyopathy: a disease of the sarcomere. Cell 1994;77:701–12.
19.
Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in
the genes for cardiac troponin T and alpha-tropomyosin in
hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058–64.
20.
Kyriakidis M, Triposkiadis F, Anastasakis A, et al. Hypertrophic
cardiomyopathy in Greece: clinical course and outcome. Chest
1998;114:1091–6.
21.
Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in
hypertrophic cardiomyopathy: identification of high risk patients.
J Am Coll Cardiol 2000;36:2212–8.
22.
Elliott PM, Gimeno B Jr., Mahon NG, Poloniecki JD, McKenna
WJ. Relation between severity of left ventricular hypertrophy
and prognosis in patients with hypertrophic cardiomyopathy.
Lancet 2001;357:420–4.
23.
Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic
cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388–94.
24.
Maron BJ, Kogan J, Proschan MA, Hecht GM, Roberts WC. Circadian
variability in the occurrence of sudden cardiac death in patients
with hypertrophic cardiomyopathy. J Am Coll Cardiol 1994;23:1405–9.
25.
Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller
FO. Sudden death in young competitive athletes. Clinical,
demographic, and pathological profiles. JAMA 1996;276:199–204.
26.
Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic
cardiomyopathy-related death: revisited in a large non–referral-based
patient population. Circulation 2000;102:858–64.
27.
Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron
BJ. Magnitude of left ventricular hypertrophy and risk of
sudden death in hypertrophic cardiomyopathy. N Engl J Med
2000;342:1778–85.
28.
Spirito P, Maron BJ. Relation between extent of left ventricular
hypertrophy and occurrence of sudden cardiac death in hypertrophic
cardiomyopathy. J Am Coll Cardiol 1990;15:1521–6.
29.
Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac
death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774–8.
30.
Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli
DM. Clinical course of hypertrophic cardiomyopathy in a regional
United States cohort. JAMA 1999;281:650–5.
31.
Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course
of hypertrophic cardiomyopathy with survival to advanced age.
J Am Coll Cardiol 2003. In Press.
32.
Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ.
Natural history of hypertrophic cardiomyopathy. A population-based
study, 1976 through 1990. Circulation 1995;92:2488–95.
33.
Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome
in patients with apical hypertrophic cardiomyopathy. J Am
Coll Cardiol 2002;39:638–45.
34.
Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural
history of hypertrophic cardiomyopathy in the elderly. J Am
Coll Cardiol 1990;16:821–6.
35.
Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy
in the elderly. Distinctions from the young based on cardiac
shape. Circulation 1989;79:580–9.
36.
Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns
of left ventricular hypertrophy in hypertrophic cardiomyopathy:
morphologic observations and significance as assessed by two
dimensional echocardiography in 600 patients. J Am Coll Cardiol
1995;26:1699–708.
37.
Maron BJ, Spirito P. Implications of left ventricular remodeling
in hypertrophic cardiomyopathy. Am J Cardiol 1998;81:1339–44.
38.
Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of
stroke in 900 patients with hypertrophic cardiomyopathy. J
Am Coll Cardiol 2002;39:301–7.
39.
Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural
mitral valve alterations in hypertrophic cardiomyopathy. Circulation
1992;85:1651–60.
40.
Yamaguchi H, Ishimura T, Nishiyama S, et al. Hypertrophic
nonobstructive cardiomyopathy with giant negative T waves
(apical hypertrophy): ventriculographic and echocardiographic
features in 30 patients. Am J Cardiol 1979;44:401–12.
41.
Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic
cardiomyopathy. Interrelations of clinical manifestations,
pathophysiology, and therapy. N Engl J Med 1987;316:844–52.
42.
Hecht GM, Klues HG, Roberts WC, Maron BJ. Coexistence of sudden
cardiac death and end-stage heart failure in familial hypertrophic
cardiomyopathy. J Am Coll Cardiol 1993;22:489–97.
43.
Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson
ME, Kieval RS. Assessment of permanent dual-chamber pacing
as a treatment for drug-refractory symptomatic patients with
obstructive hypertrophic cardiomyopathy. A randomized, double-blind,
crossover study (M-PATHY). Circulation 1999;99:2927–33.
44.
Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous
transluminal septal myocardial ablation for hypertrophic obstructive
cardiomyopathy: long term follow up of the first series of
25 patients. Heart 2000;83:326–31.
45.
Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer
WH III, Nagueh SF. Echocardiographic insights into the mechanisms
of relief of left ventricular outflow tract obstruction after
nonsurgical septal reduction therapy in patients with hypertrophic
obstructive cardiomyopathy. J Am Coll Cardiol 2001;37:208–14.
46.
Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and
long-term results after transcoronary ablation of septal hypertrophy
(TASH). Catheter interventional treatment for hypertrophic
obstructive cardiomyopathy. Eur Heart J 1999;20:1342–54.
47.
Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic
obstructive cardiomyopathy. A randomized crossover study.
PIC Study Group. Eur Heart J 1997;18:1249–56.
48.
Kappenberger LJ, Linde C, Jeanrenaud X, et al. Clinical progress
after randomized on/off pacemaker treatment for hypertrophic
obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC)
Study Group. Europace 1999;1:77–84.
49.
Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal
reduction for hypertrophic obstructive cardiomyopathy: outcome
in the first series of patients. Circulation 1997;95:2075–81.
50.
Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of
hypertrophic cardiomyopathy in an outpatient population referred
for echocardiographic study. Am J Cardiol 1994;73:577–80.
51.
Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy—pathology
and pathogenesis. Histopathology 1995;26:493–500.
52.
Louie EK, Maron BJ. Apical hypertrophic cardiomyopathy: clinical
and two-dimensional echocardiographic assessment. Ann Intern
Med 1987;106:663–70.
53.
Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy
in infants: clinical features and natural history. Circulation
1982;65:7–17.
54.
Maron BJ, Kragel AH, Roberts WC. Sudden death in hypertrophic
cardiomyopathy with normal left ventricular mass. Br Heart
J 1990;63:308–10.
55.
Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical
profile of hypertrophic cardiomyopathy identified de novo
in rural communities. J Am Coll Cardiol 1999;33:1590–5.
56.
Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy
and sudden death. N Engl J Med 1988;318:1255–7.
57.
Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis
of familial hypertrophic cardiomyopathy by genetic analysis
of blood lymphocytes. N Engl J Med 1991;325:1753–60.
58.
Skinner JR, Manzoor A, Hayes AM, Joffe HS, Martin RP. A regional
study of presentation and outcome of hypertrophic cardiomyopathy
in infants. Heart 1997;77:229–33.
59.
Maron BJ, Spirito P. Impact of patient selection biases on
the perception of hypertrophic cardiomyopathy and its natural
history. Am J Cardiol 1993;72:970–2.
60.
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN,
Hafley G. A randomized study of the prevention of sudden death
in patients with coronary artery disease. Multicenter Unsustained
Tachycardia Trial Investigators. N Engl J Med 1999;341:1882–90.
61.
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation
of a defibrillator in patients with myocardial infarction
and reduced ejection fraction. N Engl J Med 2002;346:877–83.
62.
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol
on survival in severe chronic heart failure. N Engl J Med
2001;344:1651–8.
63.
Seidman JG, Seidman CE. The genetic basis for cardiomyopathy:
from mutation identification to mechanistic paradigms. Cell
2001;104:557–67.
64.
Charron P, Dubourg O, Desnos M, et al. Clinical features and
prognostic implications of familial hypertrophic cardiomyopathy
related to the cardiac myosin-binding protein C gene. Circulation
1998;97:2230–6.
65.
Maron BJ, Niimura H, Casey SA, et al. Development of left
ventricular hypertrophy in adults in hypertrophic cardiomyopathy
caused by cardiac myosin-binding protein C gene mutations.
J Am Coll Cardiol 2001;38:315–21.
66.
Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young
trained athletes. Insights into methods for distinguishing
athlete’s heart from structural heart disease, with
particular emphasis on hypertrophic cardiomyopathy. Circulation
1995;91:1596–601.
67.
Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P.
The upper limit of physiologic cardiac hypertrophy in highly
trained elite athletes. N Engl J Med 1991;324:295–301.
68.
Palka P, Lange A, Fleming AD, et al. Differences in myocardial
velocity gradient measured throughout the cardiac cycle in
patients with hypertrophic cardiomyopathy, athletes and patients
with left ventricular hypertrophy due to hypertension. J Am
Coll Cardiol 1997;30:760–8.
69.
Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell
DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy
with gadolinium cardiovascular magnetic resonance. J Am Coll
Cardiol 2003;41:1561–7.
70.
Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath
P, Messmer BJ. Long-term clinical and echocardiographic follow-up
after surgical correction of hypertrophic obstructive cardiomyopathy
with extended myectomy and reconstruction of the subvalvular
mitral apparatus. Circulation 1995;92 Suppl:II122–7.
71.
Pollick C, Rakowski H, Wigle ED. Muscular subaortic stenosis:
the quantitative relationship between systolic anterior motion
and the pressure gradient. Circulation 1984;69:43–9.
72.
Braunwald E, Lambrew C, Rockoff D, et al. Idiopathic hypertrophic
subaortic stenosis: I. A description of the disease based
upon an analysis of 64 patients. Circulation 1964;30 Suppl
IV:3–217.
73.
Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability
of left ventricular outflow tract gradient in hypertrophic
obstructive cardiomyopathy. Circulation 1998;97:461–6.
74.
Panza JA, Maris TJ, Maron BJ. Development and determinants
of dynamic obstruction to left ventricular outflow in young
patients with hypertrophic cardiomyopathy. Circulation 1992;85:1398–405.
75.
Klues HG, Leuner C, Kuhn H. Left ventricular outflow tract
obstruction in patients with hypertrophic cardiomyopathy:
increase in gradient after exercise. J Am Coll Cardiol 1992;19:527–33.
76.
Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of
continuous wave Doppler echocardiography in the noninvasive
assessment of left ventricular outflow tract pressure gradient
in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol
1992;19:91–9.
77.
Ross J Jr., Braunwald E, Gault JH, Mason DT, Morrow AG. The
mechanism of the intraventricular pressure gradient in idiopathic
hypertrophic subaortic stenosis. Circulation 1966;34:558–78.
78.
Cohn LH, Trehan H, Collins JJ Jr. Long-term follow-up of patients
undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy.
Am J Cardiol 1992;70:657–60.
79.
Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal
septal myocardial ablation in hypertrophic obstructive cardiomyopathy:
results with respect to intraprocedural myocardial contrast
echocardiography. Circulation 1998;98:2415–21.
80.
Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D,
McAreavey D. Long-term results of dual-chamber (DDD) pacing
in obstructive hypertrophic cardiomyopathy. Evidence for progressive
symptomatic and hemodynamic improvement and reduction of left
ventricular hypertrophy. Circulation 1994;90:2731–42.
81.
Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove
DM. Surgical management of hypertrophic obstructive cardiomyopathy.
Early and late results. J Thorac Cardiovasc Surg 1995;110:195–206.
82.
Jeanrenaud X, Schlapfer J, Fromer M, Aebischer N, Kappenberger
L. Dual chamber pacing in hypertrophic obstructive cardiomyopathy:
beneficial effect of atrioventricular junction ablation for
optimal left ventricular capture and filling. Pacing Clin
Electrophysiol 1997;20:293–300.
83.
Kim JJ, Lee CW, Park SW, et al. Improvement in exercise capacity
and exercise blood pressure response after transcoronary alcohol
ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy.
Am J Cardiol 1999;83:1220–3.
84.
McIntosh CL, Maron BJ, Cannon RO III, Klues HG. Initial results
of combined anterior mitral leaflet plication and ventricular
septal myotomy-myectomy for relief of left ventricular outflow
tract obstruction in patients with hypertrophic cardiomyopathy.
Circulation 1992;86 Suppl:II60–7.
85.
Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy-myomectomy
versus mitral valve replacement in hypertrophic cardiomyopathy.
Ten-year follow-up in 185 patients. Circulation 1989;80:I57–64.
86.
Kuhn H, Gietzen FH, Schafers M, et al. Changes in the left
ventricular outflow tract after transcoronary ablation of
septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy
as assessed by transoesophageal echocardiography and by measuring
myocardial glucose utilization and perfusion. Eur Heart J
1999;20: 1808–17.
87.
Kuhn H, Gietzen F, Leuner C. “The abrupt no-flow:”
a no-reflow like phenomenon in hypertrophic cardiomyopathy.
Eur Heart J 2002;23:91–3.
88.
Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH III. Nonsurgical
septal reduction therapy for hypertrophic obstructive cardiomyopathy:
one-year follow-up. J Am Coll Cardiol 2000;36: 852–5.
89.
Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect
of pacemaker implantation in obstructive hypertrophic cardiomyopathy.
PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol 1999;83:903–7.
90.
Maron BJ, Merrill WH, Freier PA, Kent KM, Epstein SE, Morrow
AG. Long-term clinical course and symptomatic status of patients
after operation for hypertrophic subaortic stenosis. Circulation
1978; 57:1205–13.
91.
Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical
recognition and a novel operative approach for hypertrophic
cardiomyopathy with severe outflow obstruction due to anomalous
papillary muscle. Circulation 1998;98:2505–8.
92.
McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK.
Extent of clinical improvement after surgical treatment of
hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467–71.
93.
McIntosh CL, Maron BJ. Current operative treatment of obstructive
hypertrophic cardiomyopathy. Circulation 1988;78:487–95.
94.
Merrill WH, Friesinger GC, Graham TP Jr., et al. Long-lasting
improvement after septal myectomy for hypertrophic obstructive
cardiomyopathy. Ann Thorac Surg 2000;69:1732–5.
95.
Mohr R, Schaff HV, Danielson GK, Puga FJ, Pluth JR, Tajik
AJ. The outcome of surgical treatment of hypertrophic obstructive
cardiomyopathy. Experience over 15 years. J Thorac Cardiovasc
Surg 1989;97:666–74.
96.
Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol
septal reduction therapy with surgical myectomy for the treatment
of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol
2001; 38:1701–6.
97.
Nishimura RA, Hayes DL, Ilstrup DM, Holmes DR Jr., Tajik AJ.
Effect of dual-chamber pacing on systolic and diastolic function
in patients with hypertrophic cardiomyopathy. Acute Doppler
echocardiographic and catheterization hemodynamic study. J
Am Coll Cardiol 1996;27:421–30.
98.
Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing
for hypertrophic cardiomyopathy: a randomized, double-blind,
crossover trial. J Am Coll Cardiol 1997;29:435–41.
99.
Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK,
Tajik AJ. Comparison of dual-chamber pacing versus septal
myectomy for the treatment of patients with hypertropic obstructive
cardiomyopathy: a comparison of objective hemodynamic and
exercise end points. J Am Coll Cardiol 1999;34:191–6.
100.
Posma JL, Blanksma PK, Van Der Wall EE, Vaalburg W, Crijns
HJ, Lie KI. Effects of permanent dual chamber pacing on myocardial
perfusion in symptomatic hypertrophic cardiomyopathy. Heart
1996; 76:358–62.
101.
Qin JX, Shiota T, Lever HM, et al. Outcome of patients with
hypertrophic obstructive cardiomyopathy after percutaneous
transluminal septal myocardial ablation and septal myectomy
surgery. J Am Coll Cardiol 2001;38:1994–2000.
102.
Robbins RC, Stinson EB. Long-term results of left ventricular
myotomy and myectomy for obstructive hypertrophic cardiomyopathy.
J Thorac Cardiovasc Surg 1996;111:586–94.
103.
Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff
B. Management of symptomatic hypertrophic obstructive cardiomyopathy—long-term
results after surgical therapy. Thorac Cardiovasc Surg 1999;47:213–8.
104.
ten Berg JM, Suttorp MJ, Knaepen PJ, Ernst SM, Vermeulen FE,
Jaarsma W. Hypertrophic obstructive cardiomyopathy. Initial
results and long-term follow-up after Morrow septal myectomy.
Circulation 1994;90:1781–5.
105.
Theodoro DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic
obstructive cardiomyopathy in pediatric patients: results
of surgical treatment. J Thorac Cardiovasc Surg 1996;112:1589–97.
106.
Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H.
Mitral regurgitation in hypertrophic obstructive cardiomyopathy:
relationship to obstruction and relief with myectomy. J Am
Coll Cardiol 2000;36:2219–25.
107.
Gadler F, Linde C, Daubert C, et al. Significant improvement
of quality of life following atrioventricular synchronous
pacing in patients with hypertrophic obstructive cardiomyopathy.
Data from 1 year of follow-up. PIC study group. Pacing In
Cardiomyopathy. Eur Heart J 1999;20:1044–50.
108.
Ruzyllo W, Chojnowska L, Demkow M, et al. Left ventricular
outflow tract gradient decrease with non-surgical myocardial
reduction improves exercise capacity in patients with hypertrophic
obstructive cardiomyopathy. Eur Heart J 2000;21:770–7.
109.
Paz R, Jortner R, Tunick PA, et al. The effect of the ingestion
of ethanol on obstruction of the left ventricular outflow
tract in hypertrophic cardiomyopathy. N Engl J Med 1996;335:938–41.
110.
Kuhn H, Mercier J, Kohler E, Frenzel H, Hort W, Loogen F.
Differential diagnosis of hypertrophic cardiomyopathies: typical
(subaortic) hypertrophic obstructive cardiomyopathy, atypical
(midventricular) hypertrophic obstructive cardiomyopathy and
hypertrophic non-obstructive cardiomyopathy. Eur Heart J 1983;4
Suppl F:93–104.
111.
Wigle ED. Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy.
Heart 2001;86:709–14.
112.
Klues HG, Roberts WC, Maron BJ. Morphological determinants
of echocardiographic patterns of mitral valve systolic anterior
motion in obstructive hypertrophic cardiomyopathy. Circulation
1993;87:1570–9.
113.
Spirito P, Maron BJ. Patterns of systolic anterior motion
of the mitral valve in hypertrophic cardiomyopathy: assessment
by twodimensional echocardiography. Am J Cardiol 1984;54:1039–46.
114.
Qin JX, Shiota T, Lever HM, et al. Impact of left ventricular
outflow tract area on systolic outflow velocity in hypertrophic
cardiomyopathy: a real-time three-dimensional echocardiographic
study. J Am Coll Cardiol 2002;39:308–14.
115.
Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary
muscle directly into anterior mitral leaflet in hypertrophic
cardiomyopathy. Significance in producing left ventricular
outflow obstruction. Circulation 1991;84:1188–97.
116.
Maron BJ, Harding AM, Spirito P, Roberts WC, Waller BF. Systolic
anterior motion of the posterior mitral leaflet: a previously
unrecognized cause of dynamic subaortic obstruction in patients
with hypertrophic cardiomyopathy. Circulation 1983;68:282–93.
117.
Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic
anterior motion begins at low left ventricular outflow tract
velocity in obstructive hypertrophic cardiomyopathy. J Am
Coll Cardiol 2000;36:1344–54.
118.
Cape EG, Simons D, Jimoh A, Weyman AE, Yoganathan AP, Levine
RA. Chordal geometry determines the shape and extent of systolic
anterior mitral motion: in vitro studies. J Am Coll Cardiol
1989;13:1438–48.
119.
Shah PM, Taylor RD, Wong M. Abnormal mitral valve coaptation
in hypertrophic obstructive cardiomyopathy: proposed role
in systolic anterior motion of mitral valve. Am J Cardiol
1981;48:258–62.
120.
Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J.
Noninvasive assessment of left ventricular diastolic function
by pulsed Doppler echocardiography in patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol 1987;10:733–42.
121.
Wilson WS, Criley JM, Ross RS. Dynamics of left ventricular
emptying in hypertrophic subaortic stenosis. A cineangiographic
and hemodynamic study. Am Heart J 1967;73:4–16.
122.
Sherrid MV, Chu CK, Delia E, Mogtader A, Dwyer EM Jr. An echocardiographic
study of the fluid mechanics of obstruction in hypertrophic
cardiomyopathy. J Am Coll Cardiol 1993;22:816–25.
123.
Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal
Doppler echocardiography in obstructive hypertrophic cardiomyopathy:
clarification of pathophysiology and impor- tance in intraoperative
decision making. J Am Coll Cardiol 1992;20: 42–52.
124.
Petrone RK, Klues HG, Panza JA, Peterson EE, Maron BJ. Coexistence
of mitral valve prolapse in a consecutive group of 528 patients
with hypertrophic cardiomyopathy assessed with echocardiography.
J Am Coll Cardiol 1992;20:55–61.
125.
Criley JM. Unobstructed thinking (and terminology) is called
for in the understanding and management of hypertrophic cardiomyopathy.
J Am Coll Cardiol 1997;29:741–3.
126.
Murgo JP, Alter BR, Dorethy JF, Altobelli SA, McGranahan GM
Jr. Dynamics of left ventricular ejection in obstructive and
nonobstructive hypertrophic cardiomyopathy. J Clin Invest
1980;66:1369–82.
127.
Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular
outflow tract obstruction on clinical outcome in hypertrophic
cardiomyopathy. N Engl J Med 2003;348:295–303.
128.
Kofflard MJ, ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic
cardiomyopathy in a large community-based population: clinical
outcome and identification of risk factors for sudden cardiac
death and clinical deterioration. J Am Coll Cardiol 2003;41:987–93.
129.
Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring
in asymptomatic or mildly symptomatic patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol 2002;40:2156–64.
130.
Pellikka PA, Oh JK, Bailey KR, Nichols BA, Monahan KH, Tajik
AJ. Dynamic intraventricular obstruction during dobutamine
stress echocardiography. A new observation. Circulation 1992;86:1429–32.
131.
Okeie K, Shimizu M, Yoshio H, et al. Left ventricular systolic
dysfunction during exercise and dobutamine stress in patients
with hypertrophic cardiomyopathy. J Am Coll Cardiol 2000;36:856–63.
132.
Anan R, Greve G, Thierfelder L, et al. Prognostic implications
of novel beta cardiac myosin heavy chain gene mutations that
cause familial hypertrophic cardiomyopathy. J Clin Invest
1994;93:280–5.
133.
Coviello DA, Maron BJ, Spirito P, et al. Clinical features
of hypertrophic cardiomyopathy caused by mutation of a “hot
spot” in the alpha-tropomyosin gene. J Am Coll Cardiol
1997;29:635–40.
134.
Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2)
subunit of AMP-activated protein kinase cause familial hypertrophic
cardiomyopathy: evidence for the central role of energy compromise
in disease pathogenesis. Hum Mol Genet 2001;10:1215–20.
135.
Erdmann J, Raible J, Maki-Abadi J, et al. Spectrum of clinical
phenotypes and gene variants in cardiac myosin-binding protein
C mutation carriers with hypertrophic cardiomyopathy. J Am
Coll Cardiol 2001;38:322–30.
136.
Gruver EJ, Fatkin D, Dodds GA, et al. Familial hypertrophic
cardiomyopathy and atrial fibrillation caused by Arg663His
betacardiac myosin heavy chain mutation. Am J Cardiol 1999;83:13H–8H.
137.
Kimura A, Harada H, Park JE, et al. Mutations in the cardiac
troponin I gene associated with hypertrophic cardiomyopathy.
Nat Genet 1997;16:379–82.
138.
Marian AJ, Roberts R. Recent advances in the molecular genetics
of hypertrophic cardiomyopathy. Circulation 1995;92:1336–47.
139.
Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein
gene mutations in hypertrophic cardiomyopathy of the elderly.
Circulation 2002;105:446–51.
140.
Osterop AP, Kofflard MJ, Sandkuijl LA, et al. AT1 receptor
A/C1166 polymorphism contributes to cardiac hypertrophy in
subjects with hypertrophic cardiomyopathy. Hypertension 1998;32:825–30.
141.
Lechin M, Quinones MA, Omran A, et al. Angiotensin-I converting
enzyme genotypes and left ventricular hypertrophy in patients
with hypertrophic cardiomyopathy. Circulation 1995;92:1808–12.
142.
Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively
active AMP kinase mutations cause glycogen storage disease
mimicking hypertrophic cardiomyopathy. J Clin Invest 2002;109:357–62.
143.
Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry
disease in male patients with late onset hypertrophic cardiomyopathy.
Circulation 2002;105:1407–11.
144.
Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H. Fabry disease
in patients with hypertrophic cardiomyopathy (HCM). Z Kardiol
2002;91:992–1002.
145.
Jenni R, Oechslin E, Schneider J, Jost CA, Kaufmann PA. Echocardiographic
and pathoanatomical characteristics of isolated left ventricular
non-compaction: a step towards classification as a distinct
cardiomyopathy. Heart 2001;86:666–71.
146.
Charron P, Dubourg O, Desnos M, et al. Diagnostic value of
electrocardiography and echocardiography for familial hypertrophic
cardiomyopathy in a genotyped adult population. Circulation
1997;96:214–9.
147.
Charron P, Dubourg O, Desnos M, et al. Diagnostic value of
electrocardiography and echocardiography for familial hypertrophic
cardiomyopathy in genotyped children. Eur Heart J 1998;19:1377–82.
148.
Panza JA, Maron BJ. Relation of electrocardiographic abnormalities
to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy
during childhood. Am J Cardiol 1989;63:1258–65.
149.
Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic
function with Doppler tissue imaging to predict genotype in
preclinical hypertrophic cardiomyopathy. Circulation 2002;105:2992–7.
150.
Hagege AA, Dubourg O, Desnos M, et al. Familial hypertrophic
cardiomyopathy. Cardiac ultrasonic abnormalities in genetically
affected subjects without echocardiographic evidence of left
ventricular hypertrophy. Eur Heart J 1998;19:490–9.
151.
Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging
consistently detects myocardial abnormalities in patients
with hypertrophic cardiomyopathy and provides a novel means
for an early diagnosis before and independently of hypertrophy.
Circulation 2001;104:128–30.
152.
Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression
of left ventricular hypertrophy in children with hypertrophic
cardiomyopathy. N Engl J Med 1986;315:610–4.
153.
Spirito P, Maron BJ. Absence of progression of left ventricular
hypertrophy in adult patients with hypertrophic cardiomyopathy.
J Am Coll Cardiol 1987;9:1013–7.
154.
Fox PR, Liu SK, Maron BJ. Echocardiographic assessment of
spontaneously occurring feline hypertrophic cardiomyopathy.
An animal model of human disease. Circulation 1995;92:2645–51.
155.
Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse
model of familial hypertrophic cardiomyopathy. Science 1996;272:
731–4.
156.
Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade
reverses myocardial fibrosis in a transgenic mouse model of
human hypertrophic cardiomyopathy. Circulation 2001;103:789–91.
157.
Marian AJ, Wu Y, Lim DS, et al. A transgenic rabbit model
for human hypertrophic cardiomyopathy. J Clin Invest 1999;104:1683–92.
158.
Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium
channel inhibitor diltiazem prevents cardiomyopathy in a mouse
model. J Clin Invest 2002;109:1013–20.
159.
Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic
adult patients with hypertrophic cardiomyopathy. J Am Coll
Cardiol 1999;33:206–11.
160.
Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and
significance of progressive left ventricular wall thinning
and relative cavity dilatation in hypertrophic cardiomyopathy.
Am J Cardiol 1987;60:123–9.
161.
Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki
JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy:
a longitudinal study. J Am Coll Cardiol 1990;15:1279–85.
162.
Spirito P, Lakatos E, Maron BJ. Degree of left ventricular
hypertrophy in patients with hypertrophic cardiomyopathy and
chronic atrial fibrillation. Am J Cardiol 1992;69:1217–22.
163.
Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron
BJ. Impact of atrial fibrillation on the clinical course of
hypertrophic cardiomyopathy. Circulation 2001;104:2517–24.
164.
Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti
P, Vecchio C. Clinical course and prognosis of hypertrophic
cardiomyopathy in an outpatient population. N Engl J Med 1989;320:749–55.
165.
McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin
J. Prognosis in hypertrophic cardiomyopathy: role of age and
clinical, electrocardiographic and hemodynamic features. Am
J Cardiol 1981;47:532–8.
166.
Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC, Shaw
DB. Sudden death in hypertrophic cardiomyopathy: associated
accessory atrioventricular pathways. Br Heart J 1980;43:245–51.
167.
Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy:
a subset with distinctive left ventricular morphology and
progressive clinical course late in life. J Am Coll Cardiol
1989;13:36–45.
168.
Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of
negative inotropes in obstructive hypertrophic cardiomyopathy.
Circulation 1998;97:41–7.
169.
Cohen LS, Braunwald E. Amelioration of angina pectoris in
idiopathic hypertrophic subaortic stenosis with beta-adrenergic
blockade. Circulation 1967;35:847–51.
170.
Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen
Y. Treatment of hypertrophic obstructive cardiomyopathy with
verapamil. Br Heart J 1979;42:35–42.
171.
Matsubara H, Nakatani S, Nagata S, et al. Salutary effect
of disopyramide on left ventricular diastolic function in
hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol
1995;26:768–75.
172.
Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of
childhood hypertrophic cardiomyopathy: improved survival following
high-dose beta-adrenoceptor antagonist treatment. J Am Coll
Cardiol 1999;34:1813–22.
173.
Pollick C. Muscular subaortic stenosis: hemodynamic and clinical
improvement after disopyramide. N Engl J Med 1982;307:997–9.
174.
Pollick C, Kimball B, Henderson M, Wigle ED. Disopyramide
in hypertrophic cardiomyopathy. I. Hemodynamic assessment
after intravenous administration. Am J Cardiol 1988;62:1248–51.
175.
Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy:
a new approach to the pharmacologic treatment of hypertrophic
cardiomyopathy. II. Effects on exercise capacity and symptomatic
status. Circulation 1979;60:1208–13.
176.
Rosing DR, Condit JR, Maron BJ, et al. Verapamil therapy:
a new approach to the pharmacologic treatment of hypertrophic
cardiomyopathy: III. Effects of long-term administration.
Am J Cardiol 1981;48:545–53.
177.
Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for
obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988;62:1085–8.
178.
Spicer RL, Rocchini AP, Crowley DC, Rosenthal A. Chronic verapamil
therapy in pediatric and young adult patients with hypertrophic
cardiomyopathy. Am J Cardiol 1984;53:1614–9.
179.
Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo
controlled crossover trial of nadolol and verapamil in mild
and moderately symptomatic hypertrophic cardiomyopathy. J
Am Coll Cardiol 1993;21:1672–9.
180.
Frenneaux MP, Porter A, Caforio AL, Odawara H, Counihan PJ,
McKenna WJ. Determinants of exercise capacity in hypertrophic
cardiomyopathy. J Am Coll Cardiol 1989;13:1521–6.
181.
Bonow RO, Frederick TM, Bacharach SL, et al. Atrial systole
and left ventricular filling in hypertrophic cardiomyopathy:
effect of verapamil. Am J Cardiol 1983;51:1386–91.
182.
Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL,
Green MV. Verapamil-induced improvement in left ventricular
diastolic filling and increased exercise tolerance in patients
with hypertrophic cardiomyopathy: short- and long-term effects.
Circulation 1985;72:853–64.
183.
Briguori C, Betocchi S, Romano M, et al. Exercise capacity
in hypertrophic cardiomyopathy depends on left ventricular
diastolic function. Am J Cardiol 1999;84:309–15.
184.
Lele SS, Thomson HL, Seo H, Belenkie I, McKenna WJ, Frenneaux
MP. Exercise capacity in hypertrophic cardiomyopathy. Role
of stroke volume limitation, heart rate, and diastolic filling
characteristics. Circulation 1995;92:2886–94.
185.
Lewis JF, Spirito P, Pelliccia A, Maron BJ. Usefulness of
Doppler echocardiographic assessment of diastolic filling
in distinguishing “athlete’s heart” from
hypertrophic cardiomyopathy. Br Heart J 1992;68:296–300.
186.
Betocchi S, Hess OM, Losi MA, Nonogi H, Krayenbuehl HP. Regional
left ventricular mechanics in hypertrophic cardiomyopathy.
Circulation 1993;88:2206–14.
187.
Spirito P, Maron BJ, Bonow RO, Epstein SE. Severe functional
limitation in patients with hypertrophic cardiomyopathy and
only mild localized left ventricular hypertrophy. J Am Coll
Cardiol 1986;8:537–44.
188.
Spirito P, Maron BJ. Relation between extent of left ventricular
hypertrophy and diastolic filling abnormalities in hypertrophic
cardiomyopathy. J Am Coll Cardiol 1990;15:808–13.
189.
Sharma S, Elliott P, Whyte G, et al. Utility of cardiopulmonary
exercise in the assessment of clinical determinants of functional
capacity in hypertrophic cardiomyopathy. Am J Cardiol 2000;86:162–8.
190.
Cannon RO III, Schenke WH, Maron BJ, et al. Differences in
coronary flow and myocardial metabolism at rest and during
pacing between patients with obstructive and patients with
nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol
1987;10:53–62.
191.
Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G,
Camici PG. Coronary microvascular dysfunction and prognosis
in hypertrophic cardiomyopathy. N Engl J Med 2003. In Press.
192.
Grover-McKay M, Schwaiger M, Krivokapich J, Perloff JK, Phelps
ME, Schelbert HR. Regional myocardial blood flow and metabolism
at rest in mildly symptomatic patients with hypertrophic cardiomyopathy.
J Am Coll Cardiol 1989;13:317–24.
193.
Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary
flow reserve in hypertrophic cardiomyopathy is related to
remodeling of the coronary microcirculation. Circulation 1998;97:230–3.
194.
Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy
and transmural myocardial infarction without significant atherosclerosis
of the extramural coronary arteries. Am J Cardiol 1979;43:1086–102.
195.
Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (“small
vessel”) coronary artery disease in hypertrophic cardiomyopathy.
J Am Coll Cardiol 1986;8:545–57.
196.
Nienaber CA, Gambhir SS, Mody FV, et al. Regional myocardial
blood flow and glucose utilization in symptomatic patients
with hypertrophic cardiomyopathy. Circulation 1993;87:1580–90.
197.
O’Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion
abnormalities in patients with hypertrophic cardiomyopathy:
assessment with thallium-201 emission computed tomography.
Circulation 1987;76:1214–23.
198.
Takata J, Counihan PJ, Gane JN, et al. Regional thallium-201
washout and myocardial hypertrophy in hypertrophic cardiomyopathy
and its relation to exertional chest pain. Am J Cardiol 1993;72:211–7.
199.
Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai
C. Quantitative analysis of myocardial fibrosis in normals,
hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart
J 1986;55:575–81.
200.
Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis
of narrowings of intramyocardial small arteries in normal
hearts, hypertensive hearts, and hearts with hypertrophic
cardiomyopathy. Circulation 1987;75:1130–9.
201.
Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of the
architecture of subendocardial arterioles in patients with
hypertrophic cardiomyopathy and impaired coronary vasodilator
reserve: a possible cause for myocardial ischemia. J Am Coll
Cardiol 1998;31:1089–96.
202.
Ommen SR, Thomson HL, Nishimura RA, Tajik AJ, Schaff HV, Danielson
GK. Clinical predictors and consequences of atrial fibrillation
after surgical myectomy for obstructive hypertrophic cardiomyopathy.
Am J Cardiol 2002;89:242–4.
203.
Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A.
Hypertrophic cardiomyopathy and sudden death in the young:
pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:988–98.
204.
Cannon RO III, McIntosh CL, Schenke WH, Maron BJ, Bonow RO,
Epstein SE. Effect of surgical reduction of left ventricular
outflow obstruction on hemodynamics, coronary flow, and myocardial
metabolism in hypertrophic cardiomyopathy. Circulation 1989;79:766–75.
205.
Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil
on absolute myocardial blood flow in hypertrophic cardiomyopathy.
Am J Cardiol 1994;74:363–8.
206.
Udelson JE, Bonow RO, O’Gara PT, et al. Verapamil prevents
silent myocardial perfusion abnormalities during exercise
in asymptomatic patients with hypertrophic cardiomyopathy.
Circulation 1989;79:1052–60.
207.
Shirani J, Maron BJ, Cannon RO III, Shahin S, Roberts WC.
Clinicopathologic features of hypertrophic cardiomyopathy
managed by cardiac transplantation. Am J Cardiol 1993;72:434–40.
208.
Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable
cardioverter-defibrillators for the prevention of sudden death
in patients with hypertrophic cardiomyopathy. N Engl J Med
2000;342:365–73.
209.
Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E,
McKenna WJ. Survival after cardiac arrest or sustained ventricular
tachycardia in patients with hypertrophic cardiomyopathy.
J Am Coll Cardiol 1999;33:1596–601.
210.
Spirito P, Rapezzi C, Bellone P, et al. Infective endocarditis
in hypertrophic cardiomyopathy: prevalence, incidence, and
indications for antibiotic prophylaxis. Circulation 1999;99:2132–7.
211.
Roberts WC, Kishel JC, McIntosh CL, Cannon RO III, Maron BJ.
Severe mitral or aortic valve regurgitation, or both, requiring
valve replacement for infective endocarditis complicating
hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;19:365–71.
212.
Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial
endocarditis. Recommendations by the American Heart Association.
Circulation 1997;96:358–66.
213.
Autore C, Conte MR, Piccininno M, et al. Risk associated with
pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol
2002;40:1864–9.
214.
Agnew TM, Barratt-Boyes BG, Brandt PW, Roche AH, Lowe JB,
O’Brien KP. Surgical resection in idiopathic hypertrophic
subaortic stenosis with a combined approach through aorta
and left ventricle. J Thorac Cardiovasc Surg 1977;74:307–16.
215.
Spirito P, Maron BJ, Rosing DR. Morphologic determinants of
hemodynamic state after ventricular septal myotomy-myectomy
in patients with obstructive hypertrophic cardiomyopathy:
M mode and two-dimensional echocardiographic assessment. Circulation
1984;70:984–95.
216.
McIntosh CL, Greenberg GJ, Maron BJ, Leon MB, Cannon RO III,
Clark RE. Clinical and hemodynamic results after mitral valve
replacement in patients with obstructive hypertrophic cardiomyopathy.
Ann Thorac Surg 1989;47:236–46.
217.
Cooley DA, Wukasch DC, Leachman RD. Mitral valve replacement
for idiopathic hypertrophic subaortic stenosis. Results in
27 patients. J Cardiovasc Surg (Torino) 1976;17:380–7.
218.
Maron BJ, McIntosh CL, Klues HG, Cannon RO III, Roberts WC
Morphologic basis for obstruction to right ventricular outflow
in hypertrophic cardiomyopathy. Am J Cardiol 1993;71:1089–94.
219.
Marwick TH, Stewart WJ, Lever HM, et al. Benefits of intraoperative
echocardiography in the surgical management of hypertrophic
cardiomyopathy. J Am Coll Cardiol 1992;20:1066–72.
220.
Redwood DR, Goldstein RE, Hirshfeld J, et al. Exercise performance
after septal myotomy and myectomy in patients with obstructive
hypertrophic cardiomyopathy. Am J Cardiol 1979;44:215–20.
221.
Henry WL, Morganroth J, Pearlman AS, et al. Relation between
echocardiographically determined left atrial size and atrial
fibrillation. Circulation 1976;53:273–9.
222.
Rishi F, Hulse JE, Auld DO, et al. Effects of dual-chamber
pacing for pediatric patients with hypertrophic obstructive
cardiomyopathy. J Am Coll Cardiol 1997;29:734–40.
223.
Betocchi S, Losi MA, Piscione F, et al. Effects of dual-chamber
pacing in hypertrophic cardiomyopathy on left ventricular
outflow tract obstruction and on diastolic function. Am J
Cardiol 1996;77:498–502.
224.
Cannon RO III, Tripodi D, Dilsizian V, Panza JA, Fananapazir
L. Results of permanent dual-chamber pacing in symptomatic
nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 1994;73:571–6.
225.
Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002
guideline update for implantation of cardiac pacemakers and
antiarrhythmia devices: summary article: a report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines (ACC/AHA/NASPE Committee to Update
the 1998 Pacemaker Guidelines). Circulation 2002;106:2145–61.
226.
Kuhn H, Gietzen FH, Leuner C, et al. Transcoronary ablation
of septal hypertrophy (TASH): a new treatment option for hypertrophic
obstructive cardiomyopathy. Z Kardiol 2000;89 Suppl 4:IV41–54.
227.
Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic
septal ischaemia to reduce obstruction in hypertrophic obstructive
cardiomyopathy. Studies to develop a new catheter-based concept
of treatment. Eur Heart J 1997;18:846–51.
228.
Maron BJ. Role of alcohol septal ablation in treatment of
obstructive hypertrophic cardiomyopathy. Lancet 2000;355:425–6.
229.
Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular
hypertrophy after nonsurgical septal reduction therapy for
hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1492–6.
230.
Nagueh SF, Lakkis NM, He ZX, et al. Role of myocardial contrast
echocardiography during nonsurgical septal reduction therapy
for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol
1998;32:225–9.
231.
Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left
ventricular filling and left atrial function six months after
nonsurgical septal reduction therapy for hypertrophic obstructive
cardiomyopathy. J Am Coll Cardiol 1999;34:1123–8.
232.
Firoozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy
and transcoronary septal alcohol ablation in hypertrophic
obstructive cardiomyopathy: A comparison of clinical, hemodynamic
and exercise outcomes. Eur Heart J 2002;20:1617–24.
233.
Boekstegers P, Steinbigler P, Molnar A, et al. Pressure-guided
nonsurgical myocardial reduction induced by small septal infarctions
in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol
2001;38:846–53.
234.
Gietzen FH, Leuner CJ, Obergassel L, Strunk-Muller C, Kuhn
H Role of transcoronary ablation of septal hypertrophy in
patients with hypertrophic cardiomyopathy, NYHA functional
class III or IV and outflow obstruction only under provocable
conditions. Circulation 2002;106:454–9.
235.
Luria D, Klutstein MW, Rosenmann D, Shaheen J, Sergey S, Tzivoni
D. Prevalence and significance of left ventricular outflow
gradient during dobutamine echocardiography. Eur Heart J 1999;20:386–92.
236.
Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation
between myocyte disarray and outcome in hypertrophic cardiomyopathy.
Am J Cardiol 2001;88:275–9.
237.
Silka MJ, Kron J, Dunnigan A, Dick M. Sudden cardiac death
and the use of implantable cardioverter- defibrillators in
pediatric patients. The Pediatric Electrophysiology Society.
Circulation 1993;87:800–7.
238.
Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial
bridging in children with hypertrophic cardiomyopathy —a
risk factor for sudden death. N Engl J Med 1998;339:1201–9.
239.
Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients
with hypertrophic cardiomyopathy successfully resuscitated
after cardiac arrest. J Am Coll Cardiol 1989;13:1283–8.
240.
Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance
of 24 hour ambulatory electrocardiographic monitoring in patients
with hypertrophic cardiomyopathy: a prospective study. Am
J Cardiol 1981;48:252–7.
241.
Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference:
recommendations for determining eligibility for competition
in athletes with cardiovascular abnormalities. Task Force
3: hypertrophic cardiomyopathy, myocarditis and other myopericardial
diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24:880–5.
242.
McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin
JF. Arrhythmia in hypertrophic cardiomyopathy. I: Influence
on prognosis. Br Heart J 1981;46:168–72.
243.
McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival
with amiodarone in patients with hypertrophic cardiomyopathy
and ventricular tachycardia. Br Heart J 1985;53:412–6.
244.
Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A,
Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation
and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;7:701–4.
245.
Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ,
McKenna WJ. Hypertrophic cardiomyopathy: histopathological
features of sudden death in cardiac troponin T disease. Circulation
2001;104:1380–4.
246.
Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics
and prognostic implications of myosin missense mutations in
familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108–14.
247.
Watkins H. Sudden death in hypertrophic cardiomyopathy. N
Engl J Med 2000;342:422–4.
248.
Moolman JC, Corfield VA, Posen B, et al. Sudden death due
to troponin T mutations. J Am Coll Cardiol 1997;29:549–55.
249.
Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron
BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course
and outcome in an unselected regional population. J Am Coll
Cardiol 1995;26:1529–36.
250.
Adabag AS, Casey SA, Maron BJ. Sudden death in hypertrophic
cardiomyopathy: Patterns and prognostic significance of tachyarrhythmias
on ambulatory Holter ECG. Circulation 2002;106:II710.
251.
Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial
ischemia detected by thallium scintigraphy is frequently related
to cardiac arrest and syncope in young patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol 1993;22:796–804.
252.
Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A,
Cecchi F. Prognostic value of systemic blood pressure response
during exercise in a community-based patient population with
hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:2044–51.
253.
Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP,
McKenna WJ. Prospective prognostic assessment of blood pressure
response during exercise in patients with hypertrophic cardiomyopathy.
Circulation 1997;96:2987–91.
254.
Boriani G, Rapezzi C, Biffi M, Branzi A, Spirito P. Atrial
fibrillation precipitating sustained ventricular tachycardia
in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol
2002;13:954.
255.
Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force
on sudden cardiac death of the European Society of Cardiology.
Eur Heart J 2001;22:1374–450.
256.
Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M,
McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic
cardiomyopathy: an independent marker of sudden death risk
in young patients. J Am Coll Cardiol 2003. In Press.
257.
Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara
A, Maron BJ. Prognostic value of non-sustained ventricular
tachycardia and the potential role of amiodarone treatment
in hypertrophic cardiomyopathy: assessment in an unselected
non-referral based patient population. Heart 1998;79:331–6.
258.
Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic
patients with hypertrophic cardiomyopathy and nonsustained
ventricular tachycardia. Circulation 1994;90:2743–7.
259.
Ciampi Q, Betocchi S, Lombardi R, et al. Hemodynamic determinants
of exercise-induced abnormal blood pressure response in hypertrophic
cardiomyopathy. J Am Coll Cardiol 2002;40:278–84.
260.
Maron BJ, Piccininno M, Casey SA, Bernabo P, Spirito P. Relation
of extreme left ventricular hypertrophy to age in hypertrophic
cardiomyopathy. Am J Cardiol 2003;91:626–8.
261.
Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive
cardiomyopathy is part of the clinical expression of cardiac
troponin I mutations. J Clin Invest 2003;111:209–16.
262.
Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance
of the left ventricular collagen network in young patients
with hypertrophic cardiomyopathy and sudden cardiac death.
J Am Coll Cardiol 2000;35:36–44.
263.
Maron MS, Gohman TE, Casey SA, Maron BJ. Significance and
Relationship Between Magnitude of Left Ventricular Hypertrophy
and Congestive Heart Failure Symptoms in Hypertrophic Cardiomyopathy
(abstr). J Am Coll Cardiol 2002;39 Suppl A:173A.
264.
Kuck KH, Kunze KP, Schluter M, Nienaber CA, Costard A. Programmed
electrical stimulation in hypertrophic cardiomyopathy. Results
in patients with and without cardiac arrest or syncope. Eur
Heart J 1988;9:177–85.
265.
Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and
age-dependence of malignant mutations in the beta-myosin heavy
chain and troponin T genes in hypertrophic cardiomyopathy:
a comprehensive outpatient perspective. J Am Coll Cardiol
2002;39:2042–8.
266.
Van Driest SL, Ackerman MJ, Ommen SR, et al. Prevalence and
severity of “benign” mutations in the beta-myosin
heavy chain, cardiac troponin T, and alpha-tropomyosin genes
in hypertrophic cardiomyopathy. Circulation 2002;106:3085–90.
267.
Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic
determinants in hypertrophic cardiomyopathy. Prospective evaluation
of a therapeutic strategy based on clinical, Holter, hemodynamic,
and electrophysiological findings. Circulation 1992;86:730–40.
268.
Maron BJ, Estes NAM III, Maron MS, Almquist AK, Link MS, Udelson
JE. Primary prevention of sudden death as a novel treatment
strategy in hypertrophic cardiomyopathy. Circulation 2003;107:2872–5.
269.
Camm AJ, Nisam S. The utilization of the implantable defibrillator
—a European enigma. Eur Heart J 2000;21:1998–2004.
270.
Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does
sports activity enhance the risk of sudden death in adolescents
and young adults? J Am Coll Cardiol 2003. In Press.
271.
Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic
cardiomyopathy in young athletes. N Engl J Med 1998;339:364–9.
272.
Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation. A
report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines and the European
Society of Cardiology Committee for Practice Guidelines and
Policy Conferences (Committee to develop guidelines for the
management of patients with atrial fibrillation) developed
in collaboration with the North American Society of Pacing
and Electrophysiology. Eur Heart J 2001;22:1852–923.
273.
McKenna WJ, Harris L, Rowland E, et al. Amiodarone for longterm
management of patients with hypertrophic cardiomyopathy. Am
J Cardiol 1984;54:802–10.
©
2004 by the American College of Cardiology and the European
Society of Cardiology |
